Childhood Ependymoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Ependymoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (01/24/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Childhood Ependymoma

Revised text to state that certain molecular characteristics may be unfavorable prognostic factors for pediatric ependymoma.

Added text to state that chromosome 1q25 gain, which is present in approximately 20% of ependymoma cases, is reported to be prognostic for inferior outcome for both posterior fossa ependymoma and supratentorial ependymoma (cited Andreiuolo et al. as reference 20).

Added Massimino et al. as reference 29 and level of evidence 2A.

Treatment of Newly Diagnosed Childhood Ependymoma, Anaplastic Ependymoma, or RELA Fusion–Positive Ependymoma

Added Sato et al. as reference 21.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Recurrent Childhood Ependymoma

Next section >
About This PDQ Summary